Propanc Biopharma Inc (NASDAQ:PPCB – Get Free Report) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 16,903 shares, a decrease of 95.2% from the June 15th total of 352,559 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 206,327 shares, the days-to-cover ratio is presently 0.1 days.
Propanc Biopharma Trading Down 9.6%
Propanc Biopharma stock traded down $0.17 during midday trading on Friday, reaching $1.61. 218,210 shares of the stock traded hands, compared to its average volume of 3,221,563. The firm has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $4.62. The firm has a market cap of $3.67 million, a price-to-earnings ratio of -0.07 and a beta of 3.49. Propanc Biopharma has a fifty-two week low of $1.30 and a fifty-two week high of $270.25.
Propanc Biopharma announced that its Board of Directors has approved a stock repurchase plan on Thursday, June 11th that permits the company to repurchase $5.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 162.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
Hedge Funds Weigh In On Propanc Biopharma
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
Get Our Latest Research Report on Propanc Biopharma
About Propanc Biopharma
Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.
The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.
Featured Articles
- Five stocks we like better than Propanc Biopharma
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
